目的:观察头孢哌酮钠舒巴坦钠联合参麦注射液治疗老年卒中相关性肺炎(SAP)的疗效和安全性。方法:选择2016年3月-2017年3月达州市中心医院收治的84例SAP患者,按随机数字表法分为对照组(42例)和观察组(42例)。在常规治疗的基础上,对照组...目的:观察头孢哌酮钠舒巴坦钠联合参麦注射液治疗老年卒中相关性肺炎(SAP)的疗效和安全性。方法:选择2016年3月-2017年3月达州市中心医院收治的84例SAP患者,按随机数字表法分为对照组(42例)和观察组(42例)。在常规治疗的基础上,对照组患者给予注射用头孢哌酮钠舒巴坦钠3 g,加入5%葡萄糖注射液100 m L,静脉滴注,每日2次;并依据病原学检查及药敏试验结果选择合适的抗菌药物。观察组患者在对照组治疗的基础上给予参麦注射液100 m L,加入5%葡萄糖注射液250 m L中,静脉滴注,每日1次。两组患者均连续治疗2周。观察两组患者的临床疗效,治疗前后T淋巴细胞亚群(CD4^+、CD8^+、CD4^+/CD8^+)、炎症标志物[血清肿瘤坏死因子α(TNF-α)、超敏C反应蛋白(hs-CRP)、降钙素原(PCT)]水平、住院时间,并记录不良反应发生情况。结果:观察组患者总有效率(95.24%)和显效率(47.62%)均显著高于对照组的83.33%和23.81%,住院时间[(15.24±3.53)d]显著短于对照组[(18.43±4.21)d],差异均有统计学意义(P<0.05)。治疗后,两组患者CD4^+、CD4^+/CD8^+水平均显著高于同组治疗前,且观察组显著高于对照组;两组患者CD8^+、TNF-α、hs-CRP、PCT水平均显著低于同组治疗前,且观察组显著低于对照组,差异均有统计学意义(P<0.05)。两组患者不良反应总发生率比较,差异均无统计学意义(P>0.05)。结论:在常规治疗的基础上,头孢哌酮钠舒巴坦钠联合参麦注射液治疗SAP疗效显著,可有效改善患者免疫功能,降低机体炎症水平,缩短住院时间,且未增加不良反应的发生。展开更多
Acrylate-terminated poly（lactic acid）（DPLA） was synthesized by polycondensation, using lactic acid, polyalcohol and acrylic acid as the raw materials. The prepolymer products in each process were characterized by ...Acrylate-terminated poly（lactic acid）（DPLA） was synthesized by polycondensation, using lactic acid, polyalcohol and acrylic acid as the raw materials. The prepolymer products in each process were characterized by FT-IR, 1 H-NMR, GPC and DSC. DPLAs were then formulated with reactive diluent and diphenyl ketone as photoinitiator and photopolymerized into film（FPLA）. Thermal stability and degradation properties of the UV curing PLA film were studied. The results showed that the structures of prepolymer and the performances of the film could be adjusted by changing the types and content of the branching agent polyalcohol. After crosslinking modification, the degradation rate of FPLA was reduced and FPLA had better thermal stability than the pure PLA.展开更多
文摘目的:观察头孢哌酮钠舒巴坦钠联合参麦注射液治疗老年卒中相关性肺炎(SAP)的疗效和安全性。方法:选择2016年3月-2017年3月达州市中心医院收治的84例SAP患者,按随机数字表法分为对照组(42例)和观察组(42例)。在常规治疗的基础上,对照组患者给予注射用头孢哌酮钠舒巴坦钠3 g,加入5%葡萄糖注射液100 m L,静脉滴注,每日2次;并依据病原学检查及药敏试验结果选择合适的抗菌药物。观察组患者在对照组治疗的基础上给予参麦注射液100 m L,加入5%葡萄糖注射液250 m L中,静脉滴注,每日1次。两组患者均连续治疗2周。观察两组患者的临床疗效,治疗前后T淋巴细胞亚群(CD4^+、CD8^+、CD4^+/CD8^+)、炎症标志物[血清肿瘤坏死因子α(TNF-α)、超敏C反应蛋白(hs-CRP)、降钙素原(PCT)]水平、住院时间,并记录不良反应发生情况。结果:观察组患者总有效率(95.24%)和显效率(47.62%)均显著高于对照组的83.33%和23.81%,住院时间[(15.24±3.53)d]显著短于对照组[(18.43±4.21)d],差异均有统计学意义(P<0.05)。治疗后,两组患者CD4^+、CD4^+/CD8^+水平均显著高于同组治疗前,且观察组显著高于对照组;两组患者CD8^+、TNF-α、hs-CRP、PCT水平均显著低于同组治疗前,且观察组显著低于对照组,差异均有统计学意义(P<0.05)。两组患者不良反应总发生率比较,差异均无统计学意义(P>0.05)。结论:在常规治疗的基础上,头孢哌酮钠舒巴坦钠联合参麦注射液治疗SAP疗效显著,可有效改善患者免疫功能,降低机体炎症水平,缩短住院时间,且未增加不良反应的发生。
文摘目的探讨沙库巴曲缬沙坦(Sacubitril valsartan)与缬沙坦(Valsartan)对于慢性心力衰竭(Chronic heart failure,CHF)患者的早期临床预后.方法选取2019年1月~2020年1月于我院进行治疗的100名CHF患者进行研究,随机分为对照组(50例)与试验组(50例).两组均给予强心、利尿及抗CHD的基础治疗,对照组主要采用口服缬沙坦+基础治疗,试验组采用口服沙库巴曲缬沙坦+基础治疗.两组均给予治疗3周.比较两组治疗前后的心脏彩超结果、6min步行距离及疗效.结果采用沙库巴曲缬沙坦治疗的试验组LVEF(46.36±7.63 VS 41.74±8.75)与6min步行距离(397.26±78.74 VS 332.68±68.91)均显著优于对照组(P<0.05);试验组治疗有效率显著高于对照组(84%VS 62%)(P<0.05).结论沙库巴曲缬沙坦比缬沙坦更能有效改善CHD患者的心功能与运动耐量,且治疗有效率更高,临床上有一定的应用范围.
基金Funded by the National Natural Science Foundation of China(Nos.51273060,21174108)the Key Project of Hubei Provincial Department of EducationOpen Fund of Hubei Provincial Key Laboratory of Green Materials for Light Industry
文摘Acrylate-terminated poly（lactic acid）（DPLA） was synthesized by polycondensation, using lactic acid, polyalcohol and acrylic acid as the raw materials. The prepolymer products in each process were characterized by FT-IR, 1 H-NMR, GPC and DSC. DPLAs were then formulated with reactive diluent and diphenyl ketone as photoinitiator and photopolymerized into film（FPLA）. Thermal stability and degradation properties of the UV curing PLA film were studied. The results showed that the structures of prepolymer and the performances of the film could be adjusted by changing the types and content of the branching agent polyalcohol. After crosslinking modification, the degradation rate of FPLA was reduced and FPLA had better thermal stability than the pure PLA.
